Date: 2015-01-28
Type of information: Nomination
Compound:
Company: Dimension Therapeutics (USA - MA)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 28, 2015, Dimension Therapeutics, a rare disease company advancing novel treatments for diverse genetic disorders of the liver based upon an AAV gene therapy platform, announced that Mary Thistle, former senior vice president, business development at Cubist Pharmaceuticals, has been appointed to the newly created position of chief business officer. Ms. Thistle will report directly to Dimension’s CEO Annalisa Jenkins, MBBS, MRCP, and her appointment is effective February 2. Ms. Thistle brings extensive experience in the life sciences industry, serving in senior finance, operations, and business development roles. At Cubist, she was responsible for four major acquisitions, including Trius Therapeutics and Optimer Pharmaceuticals, significantly driving growth of the company’s pipeline prior to Cubist’s recent $9.5 billion acquisition by Merck. Prior to this, Ms. Thistle held leadership positions at ViaCell, Inc., including senior vice president, business development, and senior vice president and general manager, ViaCell Reproductive Health. In the latter role, she was responsible for the expansion of the company’s ViaCordTM umbilical blood-banking business, positioning ViaCell for eventual acquisition by PerkinElmer. She also helped set the stage for ViaCell’s successful IPO in her previous role as vice president, finance and corporate planning. Ms. Thistle began her career in finance as a certified public accountant working with both private and public companies. She received her B.A. degree in accounting from the University of Massachusetts.
Financial terms:
Latest news:
